Maternal serum ADAM12 levels in Down and Edwards' syndrome pregnancies at 9-12 weeks' gestation

被引:41
作者
Laigaard, Jennie
Cuckle, Howard
Wewer, Ulla M.
Christiansen, Michael
机构
[1] Statens Serum Inst, Dept Clin Biochem, DK-2300 Copenhagen, Denmark
[2] Univ Copenhagen, Rigshosp, Dept Obstet & Gynaecol, DK-2100 Copenhagen, Denmark
[3] Univ Copenhagen, Inst Mol Pathol, DK-1168 Copenhagen, Denmark
[4] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England
关键词
screening; ADAM; 12; Down syndrome; Edwards' syndrome; first trimester;
D O I
10.1002/pd.1480
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Maternal serum ADAM] 2 is reduced, on average, in early first-trimester Down and Edwards' syndrome pregnancies but the extent of reduction declines with gestation. Here we study levels at 9-12 weeks when the marker might be used concurrently with other established markers. Methods Samples from 16 Down and 2 Edwards' syndrome cases were retrieved from storage and tested together with 313 unaffected singleton pregnancies using a semi-automated time-resolved immuno-fluorometric assay. Results were expressed in multiples of the gestation-specific median (MOM) based on regression. Results The median in Down syndrome was 0.94 MoM with a 10th-90th centile range of 0.22-1.63 MoM compared with 1.00 and 0.33-2.24 MoM in unaffected controls (P = 0.21, one-side Wilcoxon Rank Sum Test). The two Edwards' syndrome cases had values 0.31 and 2.17 MoM. Conclusions ADAM 12 cannot be used concurrently with other markers in the late first trimester. However, it does have the potential to be used earlier in pregnancy either concurrently with other early markers or in a sequential or contingent protocol. More data will be required to reliably predict the performance of either approach. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:689 / 691
页数:3
相关论文
共 16 条
[1]   Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies [J].
Avgidou, K ;
Papageorghiou, A ;
Bindra, R ;
Spencer, K ;
Nicolaides, KH .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (06) :1761-1767
[2]  
Christiansen M, 1999, PRENATAL DIAG, V19, P905, DOI 10.1002/(SICI)1097-0223(199910)19:10<905::AID-PD658>3.0.CO
[3]  
2-Q
[4]   An increase in cost-effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing [J].
Christiansen, M ;
Larsen, SO .
PRENATAL DIAGNOSIS, 2002, 22 (06) :482-486
[5]  
CUCKLE H, 2004, GENETIC DISORDERS FE, P795
[6]  
Cuckle HS, 1999, PRENATAL DIAG, V19, P505, DOI 10.1002/(SICI)1097-0223(199906)19:6<505::AID-PD572>3.0.CO
[7]  
2-6
[8]   Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia [J].
Laigaard, J ;
Sorensen, T ;
Placing, S ;
Holck, P ;
Fröhlich, C ;
Wojdemann, KR ;
Sundberg, K ;
Shalmi, AC ;
Tabor, A ;
Norgaard-Pedersen, B ;
Ottesen, B ;
Christiansen, M ;
Wewer, UM .
OBSTETRICS AND GYNECOLOGY, 2005, 106 (01) :144-149
[9]   The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18 [J].
Laigaard, J ;
Christiansen, M ;
Fröhlich, C ;
Pedersen, BN ;
Ottesen, B ;
Wewer, UM .
PRENATAL DIAGNOSIS, 2005, 25 (01) :45-46
[10]   ADAM12:: a novel first-trimester maternal serum marker for Down syndrome [J].
Laigaard, J ;
Sorensen, T ;
Fröhlich, C ;
Pedersen, BN ;
Christiansen, M ;
Schiott, K ;
Uldbjerg, N ;
Albrechtsen, R ;
Clausen, HV ;
Ottesen, B ;
Wewer, UM .
PRENATAL DIAGNOSIS, 2003, 23 (13) :1086-1091